First drug candidate identified with Gain’s proprietary computational drug discovery platform SEE-Tx® to enter clinical development phase BETHESDA, Md., Sept. 12, 2023 .
Lilly Subsidiary, Scribe Ink Up-to-$1 5B CRISPR-Based Neuro Collaboration genengnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from genengnews.com Daily Mail and Mail on Sunday newspapers.
Successfully completed GLP toxicology studies for lead program GT-02287 in GBA1 Parkinson’s diseaseCompany is on track to submit application for start of Phase 1 clinical trial of GT-02287 to. | May 12, 2023
BETHESDA, Md., May 03, 2023 Gain Therapeutics, Inc. , a biotechnology company leading the discovery and development of allosteric small molecule therapies, today announced that Innosuisse, the. | May 3, 2023
Gain Therapeutics Awarded CHF 2 5 million Innosuisse Grant to Advance Lead Program in GBA1 Parkinson s Disease streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.